DexCom, Inc.
DXCM$31.7B
33.0
$2.55
График цены DXCM
Инсайдерская активность — DXCM
| Дата | Имя | Тип | Акции | Цена |
|---|---|---|---|---|
| 30.09 | Stern Sadie | Sell | 2,565 | $86.15 |
| 16.09 | Brown Michael Jon | Sell | 1,700 | $84.04 |
| 16.09 | AUGUSTINOS NICHOLAS | Sell | 1,550 | $84.02 |
| 16.09 | AUGUSTINOS NICHOLAS | Sell | 6,539 | $84.04 |
| 14.09 | Sylvain Jereme M | Sell | 3,638 | $83.27 |
| 10.09 | Boehnlein Glenn S | Sell | 0 | $0.00 |
| 10.09 | Boehnlein Glenn S | Sell | 0 | $0.00 |
| 10.09 | Boehnlein Glenn S | Sell | 0 | $0.00 |
| 10.09 | Boehnlein Glenn S | Sell | 0 | $0.00 |
| 10.09 | Boehnlein Glenn S | Sell | 0 | $0.00 |
| 10.09 | Boehnlein Glenn S | Sell | 0 | $0.00 |
| 10.09 | Boehnlein Glenn S | Sell | 0 | $0.00 |
| 10.09 | Boehnlein Glenn S | Sell | 0 | $0.00 |
| 10.09 | Boehnlein Glenn S | Sell | 0 | $0.00 |
| 10.09 | Boehnlein Glenn S | Sell | 5,841 | $0.00 |
| 10.09 | Boehnlein Glenn S | Sell | 0 | $0.00 |
| 10.09 | Boehnlein Glenn S | Sell | 0 | $0.00 |
| 10.09 | Boehnlein Glenn S | Sell | 0 | $0.00 |
| 10.09 | Boehnlein Glenn S | Sell | 0 | $0.00 |
| 10.09 | Boehnlein Glenn S | Sell | 0 | $0.00 |
Данные за последние 90 дней. Источник: SEC Filings.
Рейтинги аналитиков — DXCM
Финансовый обзор — DXCM
| Квартал | Revenue | Net Income | R&D | EPS |
|---|---|---|---|---|
| июнь 26 г. | $1.31B | $249.1M | $153.0M | $0.65 |
| март 26 г. | $1.19B | $199.5M | $145.3M | $0.52 |
| дек. 25 г. | $1.26B | $267.3M | $148.2M | $0.69 |
| сент. 25 г. | $1.21B | $283.8M | $157.5M | $0.73 |
| июнь 25 г. | $1.16B | $179.8M | $148.2M | $0.46 |
| март 25 г. | $1.04B | $105.4M | $145.2M | $0.27 |
Институциональные держатели — DXCM
| # | Фонд | Акции | Изменение | Дата |
|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 49,074,378 | - | 31.12.25 |
| 2 | BlackRock, Inc. | 38,244,137 | - | 30.06.26 |
| 3 | VANGUARD CAPITAL MANAGEMENT LLC | 25,209,752 | - | 30.06.26 |
| 4 | VANGUARD PORTFOLIO MANAGEMENT LLC | 19,656,540 | - | 30.06.26 |
| 5 | STATE STREET CORP | 18,380,806 | - | 30.06.26 |
| 6 | Invesco Ltd. | 15,288,133 | - | 30.06.26 |
| 7 | BAILLIE GIFFORD & CO | 14,801,590 | - | 30.06.26 |
| 8 | GEODE CAPITAL MANAGEMENT, LLC | 12,426,515 | - | 30.06.26 |
| 9 | ALLIANCEBERNSTEIN L.P. | 11,693,409 | - | 30.06.26 |
| 10 | UBS ASSET MANAGEMENT AMERICAS INC | 11,261,876 | - | 30.06.26 |
О компании DexCom, Inc.
DexCom, Inc. is a medical technology company primarily focused on innovating, developing, and marketing continuous glucose monitoring (CGM) systems. Operating across the United States and internationally, the firm provides its solutions for individuals managing diabetes as well as for healthcare practitioners. Its product portfolio features the DexCom G6, a comprehensive CGM system for diabetes management; the Dexcom Real-Time API, enabling authorized third-party developers to integrate live CGM data into their digital health applications; the Dexcom ONE, which aims to supersede traditional finger-prick blood glucose testing for treatment decisions; and Dexcom Share, a remote monitoring platform. The company is also developing the Dexcom G7, its next-generation CGM system. Furthermore, DexCom, Inc. has a licensing and collaboration agreement with Verily Life Sciences LLC and Verily Ireland Limited to advance blood-based or interstitial glucose monitoring products. The company directly sells its offerings to specialists such as endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and maintains its headquarters in San Diego, California.
Отказ от ответственности: Данные предоставлены Financial Modeling Prep API. Информация носит справочный характер и не является инвестиционной рекомендацией. Котировки могут обновляться с задержкой до 15 минут.